ReviewClinical and experimental immunology2012
Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction.
Review in Clinical and experimental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Machine Learning Developed a MYC Expression Feature-Based Signature for Predicting Prognosis and Chemoresistance in Pancreatic Adenocarcinoma.Biochemical genetics · 2024Article
- Oncogenes in immune cells as potential therapeutic targets.ImmunoTargets and therapy · 2018Review
- Chemotherapy Resistance Mechanisms in Advanced Skin Cancer.Oncology reviews · 2017Review
- MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.Oncogene · 2016Review
- Myc coordinates transcription and translation to enhance transformation and suppress invasiveness.EMBO reports · 2015Article
- SGF29 and Sry pathway in hepatocarcinogenesis.World journal of biological chemistry · 2015Review
- Article
- Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model.BioEssays : news and reviews in molecular, cellular and developmental biology · 2014Article
- Inactivation of MYC reverses tumorigenesis.Journal of internal medicine · 2014Review
- MYC activation is a hallmark of cancer initiation and maintenance.Cold Spring Harbor perspectives in medicine · 2014Review
- Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.Expert opinion on investigational drugs · 2013Review
- Noncanonical roles of the immune system in eliciting oncogene addiction.Current opinion in immunology · 2013Review
- Kidney transplantation and the ageing immune system.Nature reviews. Nephrology · 2012Review
- Broadening the translational immunology landscape.Clinical and experimental immunology · 2012Article
- Elevated neutrophil elastase and acrolein-protein adducts are associated with W256 regression.Clinical and experimental immunology · 2012Article
- Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptations.Annals of the New York Academy of Sciences · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Despite complex genomic and epigenetic abnormalities, many cancers are irrevocably dependent on an initiating oncogenic lesion whose restoration to a normal physiological activation can elicit a dramatic and sudden reversal of their neoplastic properties. This phenomenon of the reversal of tumorigenesis has been described as oncogene addiction. Oncogene addiction had been thought to occur largely through tumour cell-autonomous mechanisms such as proliferative arrest, apoptosis, differentiation and cellular senescence. However, the immune system plays an integral role in almost every aspect of tumorigenesis, including tumour initiation, prevention and progression as well as the response to therapeutics. Here we highlight more recent evidence suggesting that oncogene addiction may be integrally dependent upon host immune-mediated mechanisms, including specific immune effectors and cytokines that regulate tumour cell senescence and tumour-associated angiogenesis. Hence, the host immune system is essential to oncogene addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.